Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

181. Variations in subclinical left ventricular dysfunction, functional capacity, and clinical outcomes in different heart failure aetiologies Full Text available with Trip Pro

Variations in subclinical left ventricular dysfunction, functional capacity, and clinical outcomes in different heart failure aetiologies Patients with heart failure (HF) risk factors are described as being in Stage A of this condition (SAHF). Management is directed towards prevention of HF progression, but to date, no evidence has been described to align the intensity of this intervention to HF risk. We sought to what extent SAHF of Type 2 diabetes mellitus (T2DM) and other HF risks showed (...)  = 0.034), and GLS (HR = 1.14; P = 0.033) were independently associated with the primary endpoint in T2DM-SAHF, independent of age and glycaemic control.The T2DM-SAHF has worse subclinical left ventricular function, exercise capacity, and prognosis than other-SAHF. Impaired GLS, atrial fibrillation, exercise capacity, and obesity are associated with a worse prognosis in T2DM-SAHF but not in other-SAHF.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European

2018 ESC heart failure

182. Mineralocorticoid receptor antagonists for heart failure: a real‐life observational study Full Text available with Trip Pro

Mineralocorticoid receptor antagonists for heart failure: a real‐life observational study Mineralocorticoid receptor antagonists (MRAs) have been demonstrated to improve outcomes in reduced ejection fraction heart failure (HFrEF) patients. However, MRAs added to conventional treatment may lead to worsening of renal function and hyperkalaemia. We investigated, in a population-based analysis, the long-term effects of MRA treatment in HFrEF patients.We analysed data of 6046 patients included (...) in the Metabolic Exercise Cardiac Kidney Index score dataset. Analysis was performed in patients treated (n = 3163) and not treated (n = 2883) with MRA. The study endpoint was a composite of cardiovascular death, urgent heart transplantation, or left ventricular assist device implantation. Ten years' survival was analysed through Kaplan-Meier, compared by log-rank test and propensity score matching. At 10 years' follow-up, the MRA-untreated group had a significantly lower number of events than the MRA-treated

2018 ESC heart failure

183. Catheter Ablation for Atrial Fibrillation with Heart Failure. Full Text available with Trip Pro

Catheter Ablation for Atrial Fibrillation with Heart Failure. Mortality and morbidity are higher among patients with atrial fibrillation and heart failure than among those with heart failure alone. Catheter ablation for atrial fibrillation has been proposed as a means of improving outcomes among patients with heart failure who are otherwise receiving appropriate treatment.We randomly assigned patients with symptomatic paroxysmal or persistent atrial fibrillation who did not have a response (...) to antiarrhythmic drugs, had unacceptable side effects, or were unwilling to take these drugs to undergo either catheter ablation (179 patients) or medical therapy (rate or rhythm control) (184 patients) for atrial fibrillation in addition to guidelines-based therapy for heart failure. All the patients had New York Heart Association class II, III, or IV heart failure, a left ventricular ejection fraction of 35% or less, and an implanted defibrillator. The primary end point was a composite of death from any

2018 NEJM Controlled trial quality: predicted high

184. Worsening renal function definition is insufficient for evaluating acute renal failure in acute heart failure Full Text available with Trip Pro

Worsening renal function definition is insufficient for evaluating acute renal failure in acute heart failure Whether or not the definition of a worsening renal function (WRF) is adequate for the evaluation of acute renal failure in patients with acute heart failure is unclear.One thousand and eighty-three patients with acute heart failure were analysed. A WRF, indicated by a change in serum creatinine ≥0.3 mg/mL during the first 5 days, occurred in 360 patients while no-WRF, indicated (...) presence of AKI on admission, especially Class I and Class F status, is associated with a poor prognosis despite the lack of a WRF within the first 5 days. The prognostic ability of AKI on admission may be superior to WRF within the first 5 days.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure

185. Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study Full Text available with Trip Pro

Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study The aim of this study was to assess the prognostic value of chronic kidney disease (CKD) in relation to ischaemic stroke, intracranial haemorrhage, major bleeding, and all-cause death in heart failure patients without atrial fibrillation.In this observational cohort study, heart failure patients without atrial fibrillation were identified using Danish nationwide registries. Risk (...) of stroke, major haemorrhage, and death were calculated after 1 and 5 years to compare patients with and without CKD, ±dialysis [dialysis: CKD with renal replacement therapy (CKD-RRT); no dialysis: CKD-no RRT]. A total of 43 199 heart failure patients were included, among which 0.8% had CKD-RRT and 5.9% had CKD-no RRT. When compared with heart failure patients without CKD, both CKD-RRT and CKD-no RRT were associated with a higher 5 year rate of major bleeding (CKD-RRT: adjusted hazard ratio (aHR): 2.91

2018 ESC heart failure

186. N‐terminal pro‐B‐type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure Full Text available with Trip Pro

N‐terminal pro‐B‐type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure N-terminal pro-B-type natriuretic peptide (NT-proBNP) is the most frequently used biomarker in heart failure (HF), but its prognostic utility across ethnicities is unclear.This study included 546 Caucasians with HF from the Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure and 578 Asians with HF from the Singapore Heart Failure Outcomes and Phenotypes (...) ejection fraction in Asian (Pinteraction  = 0.776) and Caucasian patients (Pinteraction  = 0.558).NT-proBNP has similar prognostic performance in Asians and Caucasians with HF despite ethnic differences in known clinical determinants of plasma NT-proBNP.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure

187. Subcutaneous implantable cardioverter defibrillator in patients awaiting cardiac transplantation or left ventricular assist device for refractory heart failure: a feasible alternative to transvenous device? Full Text available with Trip Pro

Subcutaneous implantable cardioverter defibrillator in patients awaiting cardiac transplantation or left ventricular assist device for refractory heart failure: a feasible alternative to transvenous device? 29377556 2018 12 17 2018 12 17 2055-5822 5 3 2018 06 ESC heart failure ESC Heart Fail Subcutaneous implantable cardioverter defibrillator in patients awaiting cardiac transplantation or left ventricular assist device for refractory heart failure: a feasible alternative to transvenous device (...) of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy. Gerosa Gino G Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy. Iliceto Sabino S Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy. eng Editorial 2018 01 27 England ESC Heart Fail 101669191 2055-5822 IM Defibrillators, Implantable Feasibility Studies Heart Failure surgery Heart Transplantation Heart-Assist Devices Humans Subcutaneous Tissue Waiting

2018 ESC heart failure

188. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease Full Text available with Trip Pro

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease Hyperkalaemia risk precludes optimal renin-angiotensin-aldosterone system inhibitor use in patients with heart failure (HF), particularly those with chronic kidney disease (CKD). Patiromer is a sodium-free, non-absorbed potassium (K+ )-binding polymer approved for the treatment of hyperkalaemia. In PEARL-HF, patiromer 25.2 g (fixed dose (...) to spironolactone 50 mg/day, patiromer was well tolerated, with a low incidence of hyperkalaemia, hypokalaemia, and hypomagnesaemia.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure Controlled trial quality: uncertain

189. SSRIs for depression/heart failure patients? Not so fast

SSRIs for depression/heart failure patients? Not so fast SSRIs for depression/heart failure patients? Not so fast Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics SSRIs for depression/heart failure patients? Not so fast View/ Open Date 2017-09 Format Metadata Abstract This study should put to rest the practice (...) of starting SSRIs in depressed patients with heart failure in an attempt to affect CVD outcomes. PRACTICE CHANGER: Do not prescribe selective serotonin reuptake inhibitors to improve depression and reduce cardiovascular risk in patients with congestive heart failure. Stength of recommendation: B: Based on one large randomized controlled trial. URI Part of Citation Journal of Family Practice, 66(9) 2017: 564-567. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial

2018 PURLS

190. Eligibility of sacubitril–valsartan in a real‐world heart failure population: a community‐based single‐centre study Full Text available with Trip Pro

Eligibility of sacubitril–valsartan in a real‐world heart failure population: a community‐based single‐centre study This study aims to investigate the eligibility of the Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor (ARNI) with ACE inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) study to a real-world heart failure population.Medical records of all heart failure patients living within the catchment area of Umeå (...) University Hospital were reviewed. This district consists of around 150 000 people. Out of 2029 patients with a diagnosis of heart failure, 1924 (95%) had at least one echocardiography performed, and 401 patients had an ejection fraction of ≤35% at their latest examination. The major PARADIGM-HF criteria were applied, and 95 patients fulfilled all enrolment criteria and thus were eligible for sacubitril-valsartan. This corresponds to 5% of the overall heart failure population and 24% of the population

2018 ESC heart failure

191. Single‐dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo‐controlled study (PRACTICE‐ASIA‐HF) Full Text available with Trip Pro

Single‐dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo‐controlled study (PRACTICE‐ASIA‐HF) Iron deficiency is highly prevalent in Southeast Asians with heart failure (HF) and associated with worse outcomes. This trial aimed to assess the effect of intravenous iron in Southeast Asians hospitalized with decompensated HF.Fifty patients hospitalized for acute decompensated HF, regardless of ejection fraction, with iron deficiency (defined as serum (...) % CI -8.27 to 5.31, P = 0.670) and VAS 0.26 (95% CI -0.33 to 0.86, P = 0.386)]. FCM was well tolerated with no serious treatment-related adverse events.Intravenous FCM administered pre-discharge in Southeast Asians hospitalized with decompensated HF is clinically feasible. Changes in 6MWT distance should be measured beyond Week 12 to account for background therapy effects.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

2018 ESC heart failure Controlled trial quality: predicted high

192. Low NT‐proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction Full Text available with Trip Pro

in half of this obese study cohort. Cardiac diastolic dysfunction and cardiorespiratory fitness were not significantly different between high and low NT-proBNP patients. These data indicate that excluding the diagnosis of HFpEF based solely on NT-proBNP levels should be discouraged.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. (...) Low NT‐proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome that presents clinicians with a diagnostic challenge. The use of natriuretic peptides to exclude a diagnosis of HFpEF has been proposed. We sought to compare HFpEF patients with N-terminal pro-brain natriuretic peptide (NT-proBNP) level above and below the proposed cut-off.Stable

2018 ESC heart failure

193. The effect of diuresis on extravascular lung water and pulmonary function in acute decompensated heart failure Full Text available with Trip Pro

The effect of diuresis on extravascular lung water and pulmonary function in acute decompensated heart failure The effect of extravascular lung water (EVLW) and relationship to functional status as a result of acute decompensated heart failure (ADHF) are not well understood. We sought to quantify changes in clinical variables, EVLW, airway anatomy, spirometry, and diffusing capacity for carbon monoxide before and after treatment for ADHF.Fifteen patients were recruited within 24 h of hospital (...) change: alveolar-capillary membrane conductance/capillary blood volume, 23.4 ± 22.8%). Weight loss during hospitalization was significantly correlated with improved spirometry and diffusing capacity.Extravascular lung water contributes to the pulmonary congestive syndrome in ADHF patients, and its clearance is an important component of the improvement in pulmonary function as a result of inpatient treatment.© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf

2018 ESC heart failure

194. Effects of intravenous home dobutamine in palliative end‐stage heart failure on quality of life, heart failure hospitalization, and cost expenditure Full Text available with Trip Pro

Effects of intravenous home dobutamine in palliative end‐stage heart failure on quality of life, heart failure hospitalization, and cost expenditure In patients with palliative end-stage heart failure, interventions that could provide symptomatic relief and prevent hospital admissions are important. Ambulatory continuous intravenous inotropes have been advocated by guidelines for such a purpose. We sought to determine the effect of intravenous dobutamine on symptomatic status, hospital stay (...) , mortality, and cost expenditure.All consecutive end-stage heart failure patients not amenable for advanced therapies and discharged with continuous intravenous home dobutamine from a single tertiary centre between April 2011 and January 2017 were retrospectively analysed. Dobutamine (fixed dose) was infused through a single-lumen central venous catheter with a small pump that was refilled by a nurse on a daily basis. Symptomatic status was longitudinally assessed as the change in New York Heart

2018 ESC heart failure

195. Automating Quality Measures for Heart Failure Using Natural Language Processing: A Descriptive Study in the Department of Veterans Affairs Full Text available with Trip Pro

Automating Quality Measures for Heart Failure Using Natural Language Processing: A Descriptive Study in the Department of Veterans Affairs We developed an accurate, stakeholder-informed, automated, natural language processing (NLP) system to measure the quality of heart failure (HF) inpatient care, and explored the potential for adoption of this system within an integrated health care system.To accurately automate a United States Department of Veterans Affairs (VA) quality measure (...) for inpatients with HF.We automated the HF quality measure Congestive Heart Failure Inpatient Measure 19 (CHI19) that identifies whether a given patient has left ventricular ejection fraction (LVEF) <40%, and if so, whether an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker was prescribed at discharge if there were no contraindications. We used documents from 1083 unique inpatients from eight VA medical centers to develop a reference standard (RS) to train (n=314) and test (n=769

2018 JMIR medical informatics

196. Higher vitamin D intake could improve sleep and cognitive outcomes in older adults with heart failure

Higher vitamin D intake could improve sleep and cognitive outcomes in older adults with heart failure Higher vitamin D intake could improve sleep and cognitive outcomes in older adults with heart failure | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Higher vitamin D intake could improve sleep and cognitive outcomes in older adults with heart failure Article Text Commentary Nursing issues Higher vitamin D intake could improve sleep

2018 Evidence-Based Nursing

197. Heart Failure Full Text available with Trip Pro

. Strong FOR Low Invasive coronary angiography should be considered in patients with heart failure associated with refractory angina, resuscitated cardiac arrest, sustained ventricular arrhythmias, or with evidence of ischaemic heart disease on other investigations, or an intermediate-to-high pretest probability for coronary artery disease, to determine the need for coronary revascularisation. Strong FOR Low Either computed tomography (CT) coronary angiography or cardiac magnetic resonance imaging (CMR (...) receptor neprilysin inhibitor; AV, atrioventricular; BNP, B-type natriuretic peptide; BP, blood pressure; bpm, beats per minute; CABG, coronary artery bypass graft; CMR, cardiac magnetic resonance imaging; CRT, cardiac resynchronisation therapy; CT, computed tomography; ECG, electrocardiogram; DCM, dilated cardiomyopathy; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter defibrillator; LGE, late

2018 Cardiac Society of Australia and New Zealand

198. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018 National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018 | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname (...) Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018 John J Atherton, Andrew Sindone, Carmine G De Pasquale, Andrea Driscoll, Peter S MacDonald, Ingrid Hopper, Peter Kistler, Tom G

2018 MJA Clinical Guidelines

199. Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart Failure: A Rapid Qualitative Review

Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart Failure: A Rapid Qualitative Review Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart Failure: A Rapid Qualitative Review | CADTH.ca Find the information you need Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart Failure: A Rapid Qualitative Review Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart (...) Failure: A Rapid Qualitative Review Last updated: September 17, 2018 Project Number: RC1019-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question How do patients experience, make decisions around, and live with outpatient cardiac monitors for the diagnosis of stroke, atrial fibrillation, and/or heart failure? Key Message The onset of cardiac monitor use accompanies many life changes and new personal responsibilities. For some

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

200. One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Ran Full Text available with Trip Pro

One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Ran In patients with heart failure (HF) and left ventricular ejection fraction (LVEF) equal to or greater than 40%, a transcatheter interatrial shunt device (IASD; Corvia Medical) reduces exercise pulmonary capillary wedge pressure (PCWP (...) centers in the United States, Europe, and Australia on patients with New York Heart Association (NYHA) class III or ambulatory class IV HF, LVEF equal to or greater than 40%, exercise PCWP equal to or greater than 25 mm Hg, and PCWP-right atrial pressure gradient equal to or greater than 5 mm Hg.Safety was assessed by major adverse cardiac, cerebrovascular, or renal events (MACCRE). Exploratory outcomes evaluated at 1 year were hospitalizations for HF, NYHA class, quality of life, a 6-minute walk test

2018 JAMA cardiology Controlled trial quality: predicted high